Brief: Fusion Antibodies Says Revenues For FY2024 Expected To Be Significantly Weighted Towards H2
04/12/2023 07:17
Dec 4 (Reuters) - Fusion Antibodies PLC FAB.L :
* REVENUES FOR FY2024 ARE EXPECTED TO BE SIGNIFICANTLY
WEIGHTED
TOWARDS SECOND HALF OF FINANCIAL YEAR
Source text for Eikon: ID:nRSD4785Va
Further company coverage: FAB.L
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Fusion Antibodies
See all newsBrief: Fusion Antibodies Announces New TGE And Cryoem Project With US Pharma Client
Fusion Antibodies - Contract win
Fusion Antibodies - AGM statement H1 trading and research update
RCS - Fusion Antibodies - Launch of new customer-focused website
Fusion Antibodies - Posting of Annual Report & Notice of AGM